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Abstract
Peripheral nerve injuries are frequent and represent a significant pathology of the periph‐
eral nervous system because, despite operative techniques and successful microsurgical 
repair, in most cases, the nerve repair is followed by scar formation. Numerous inves‐
tigations have been carried out with the aim of finding pharmacological substances 
that can prevent scar formation and speed up the regeneration of repaired nerves. This 
chapter is dedicated to the efforts of many researchers to find different pharmacological 
agents with local effects on the improvement of nerve regeneration. Numerous experi‐
ments have been carried out in mice and rabbits using hyaluronic acid, tacrolimus, 
cyclosporin A, melatonin, vitamin B12, methylprednisolone, riluzole and potassium and 
calcium channel blockers. In the experimental animal studies, topical pharmacological 
agents were used at the site of peripheral nerve repair. The effect of these substances 
is most commonly studied in sciatic nerve injury in experimental animals. Their effects 
were evaluated using a variety of methods, such as morphological, biomechanical, elec‐
trophysiological and functional evaluation, and the above‐mentioned substances, have 
been shown to have neuroprotective and neuroregenerative properties though different 
mechanisms.
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1. Introduction
The peripheral nervous system (PNS) is very complex, being composed of the cranial nerves 
and the spinal nerves, which project from the spinal cord and pass through the intervertebral 
foramina of the vertebrae [1]. Peripheral nerves, composed of motor and sensory neurons, 
are considered as complex organs and are present in nearly all parts of the human body [2]. 
Motor neurons transmit processed information from the central nervous systems (CNS) to 
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skeletal muscles via efferent pathways, whereas collected information from periphery travels 
to the brain via afferent pathways, after they are translated into nerve signals [3]. Neurons are 
the main cells of the PNS, but there are two kinds of neuroglia in the PNS, namely Schwann 
cells and satellite cells. Neurons are made up of the body (soma) and their thin processes of 
the cell, which are called dendrites and axons. In the soma of the neuron, there are many types 
of organelles [4]. Based on the number of extensions that arise from the cell body, neurons can 
be multipolar (three or more extensions), bipolar (two extensions, one axon and one dendrite) 
or unipolar (only one extension), which are very short and divided in the form of a letter T [5].
Peripheral nerve injuries (PNIs) are very common, and automobile accidents are the most 
common cause of nerve trauma [6], with most cases (75%) occurring in the upper limbs [7]. 
However, the etiological factors of PNI are different in peace and conflict periods, and, histori‐
cally, most knowledge of PNIs was developed during wars [8]. Nerve injuries can be caused 
by lacerations with sharp objects, penetrating trauma, stretching or crushing trauma, fractures 
and wounds [9]. Lacerations, especially those which were caused by a knife blade, are another 
common cause of PNIs, comprising 30% of serious injuries in some series [10]. Compression 
is another common cause of PNIs, including ‘Saturday Night Palsy’ caused by radial nerve 
compression, which causes entrapment neuropathies [11]. The most severe form of nerve 
injury is a transection, which is known as grade V neurotmesis, usually owing to a laceration 
from a knife, firearm or glass shard [12]. The neurotmesis is characterised with a full transec‐
tion of the axons and connective tissue layers wherein complete discontinuity of the nerve is 
observed [13]. There are numerous classifications of nerve injuries, but of these classifications, 
the most widely accepted are those developed by Seddon and Sunderland [14, 15].
After a peripheral nerve sustains a traumatic injury, complex pathophysiologic changes, such 
as morphologic and metabolic changes, occur at the injury site [16]. Furthermore, these com‐
plex changes occur in the nerve cell body, in the proximal and distal segments to the injury 
site, as well as in the distal endings of both muscle end‐plates and sensory receptors [17]. 
These changes are characterised by axonal degeneration, which follows a sequence of events 
within the zone of trauma extending both proximally and distally [18]. Disconnected axons 
and cell bodies (in proximal axon injuries) degenerate via chromatolysis [19]. The degenera‐
tive changes in the distal segment were first described by Waller in 1850 based on observations 
of frog glossopharyngeal and hypoglossal nerves after injury [20]. Wallerian degeneration 
starts almost immediately after axotomy and lasts for 3–6 weeks [17].
The regenerative process begins almost immediately after nerve injury. The first wave of axonal 
sprouting occurs within hours of axotomy [21]. Two days after this first wave of axonal sprout‐
ing, a second wave of this process of regeneration starts [22]. According to some authors, axons 
may branch once they reach the distal stump, and in these cases, one axon may give rise to 
several branches [23]. It is known that Schwann cells play an important role in nerve regenera‐
tion at the site of nerve injury because they elaborate processes that include physical conduits 
that lead axons to their targets [17]. The extension of Schwann cells’ processes can limit the 
rate of axon regeneration more than axonal growth [24]. Regeneration of the damaged periph‐
eral nerve depends on the microsurgical procedure performed. Currently, there are several 
operating techniques that can be used to repair injured nerves, such as direct  epineural repair, 
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grouped fascicular repair, fascicular repair and nerve grafting [25]. However, there are some 
factors that influence the regeneration process after nerve repair, such as the nature, location 
and extent of damage, the extent and timing of repair, fascicular anatomy and patient factors 
(age, physical condition, metabolic disorders, avitaminosis and the presence of any disease).
In addition, recently some experimental studies have shown that nerve regeneration after 
its repair can be improved by some pharmaceutical agents, mainly used locally at the site of 
nerve repair. Drugs commonly used for this purpose include tacrolimus [26–29], hyaluronic 
acid and its derivatives [30–32], melatonin [33–35], methylprednisolone [36–39], vitamin 
B complex and vitamin B12, [40–42], calcium and potassium channel blockers [43, 44] and 
riluzole [45, 46]. These substances have neuroprotective and neuroregenerative properties, 
though different mechanisms contribute markedly to nerve regeneration.
Therefore, the main aim of this chapter is to present new insights into the mechanisms of action 
of many of the above‐mentioned pharmacological agents on the prevention of perineural scar 
formation and on nerve regeneration after peripheral nerve surgery. However, it is under‐
standable that complete regeneration and functional recovery will almost never be achieved, 
regardless of the operative technique used or the type of pharmacological agent applied.
2. Hyaluronic acid
Hyaluronic acid (HA) (CAS No. 9004‐61‐9) is a natural glycosaminoglycan formed by bond‐
ing N‐acetyl‐d‐glucosamine with glucuronic acid [47]. It is a mucopolysaccharide, which 
occurs naturally in all living organisms, and is several thousands of sugars (carbohydrates) 
long. Disaccharide units are formed at the plasma membrane in vertebrates and some bacteria 
[48, 49]. HA is characterised by a very large number of disaccharide pairs (10,000 or more), 
so its molecular mass is approximately 4 million Da [50]. HA was discovered in bovine vitre‐
ous humour by Meyer and Palmer in 1934. These authors found that the HA contained two 
sugar molecules, one of which was uronic acid, and they proposed the name ‘hyaluronic acid’ 
[51], while the term ‘hyaluronan’ was introduced in 1986 by Endre Balazs to conform with 
the international nomenclature of polysaccharides [52]. HA is a major primary component 
in the extracellular matrix, but it has also been found intracellularly. HA has been isolated 
from many other sources, and its physicochemical structural properties and biological role 
have been studied in numerous laboratories [53]. The biosynthesis of HA has been studied 
for over six decades, but our understanding of the biochemical details of HA assembly is 
still incomplete. The enzyme responsible, HA synthase (HAS), is a membrane protein that 
requires only Mg2+ and two sugar‐UDP substrates (GlcUA‐UDP and GlcNAc‐UDP) to poly‐
merise HA chains [54]. In 1993, the hasA gene was identified and cloned, and the HAS protein 
from Streptococcus pyogenes was expressed [55, 56]. It was also demonstrated that only the 
HAS protein was required to synthesise HA [57]. It is known that mammalian genomes have 
three different HAS genes (HAS1, HAS2 and HAS3) that are expressed at specific times and 
in specific tissues during development, ageing and wound healing, as well as under normal 
and some pathologic conditions [58, 59].
The Role of Pharmacological Agents in Nerve Regeneration after Peripheral Nerve Repair
http://dx.doi.org/10.5772/intechopen.68378
149
HA has numerous biological functions, such as maintenance of the elastoviscosity of liquid 
connective tissues, for example, in joint synovial and eye vitreous fluid, control of tissue 
hydration and water transport, as well as supramolecular assembly of proteoglycans in the 
extracellular matrix. Furthermore, HA has various receptor‐mediated roles in cell detach‐
ment, mitosis, migration, tumour development and metastasis, and inflammation [52, 60]. 
The predominant role of HA in organisms is unknown, but some clinical studies have demon‐
strated various physiological effects of exogenous HA. Exogenous HA enhances chondrocyte 
HA and proteoglycan synthesis, reduces the reproduction and activity of proinflammatory 
mediators, such as matrix metalloproteinases, and alters the behaviour of immune cells [61]. 
HA has also been successfully used in peripheral nerve surgery to reduce nerve adhesions 
during wound healing after nerve injury, which occur during ophthalmological, cardiovas‐
cular and dermatological procedures, including supplementing joint fluid in arthritis [32, 62, 
63]. HA is known to reduce the extent of scar formation and nerve adhesions via the inhibi‐
tion of lymphocyte migration, proliferation and chemotaxis of granulocyte phagocytosis and 
degranulation, and macrophage motility in order improve peripheral nerve regeneration [31, 
64]. These functions are manifested during scavenging of reactive oxygen‐derived free radi‐
cals, the inhibition of immune complex adherence to polymorphonuclear cells, the inhibition 
of leucocyte and macrophage migration and aggregation, and the regulation of fibroblast 
proliferation [65]. HA is an endogenous stimulator of interleukin‐1 (IL‐1) production, and 
IL‐1 affects fibroblasts proliferation and collagenase production [30]. Therefore, according 
to Hiro et al., HA is an endogenous IL‐1 inducer and may play important roles in the patho‐
logical and/or physiological changes of connective tissues [30]. It is known that HA is highly 
non‐antigenic and non‐immunogenic, because it has high structural homology across species 
and weak interactions with blood components [66]. HA’s degradation products are thought 
to contribute in scar formation because the increased amounts of HA fragments from the 
action of hyaluronidase in HA induce increased scar formation. There are various commercial 
preparations of HA in different forms, such as films, microspheres, liposomes, fibres and 
hydrogels, which have been used for more than 20 years worldwide [63]. Although the above‐
mentioned commercial preparations of HA have mainly been used in animal studies, it also 
provides useful information regarding the effect of hyaluronate in the prevention of post‐
operative peridural scar adhesion after laminectomy in spine surgery; however, additional 
clinical trials regarding the use of HA‐based gels should be performed to confirm its effects 
in human subjects [67, 68]. Use of the hyaluronic acid‐carboxymethylcellulose membrane 
Seprafilm as a solid anti‐adhesion barrier agent is one of the therapeutic approaches used to 
reduce postoperative scar formation and is effective in promoting peripheral nerve regenera‐
tion at the repair site [69]. In addition, HA‐carboxymethylcellulose solutions improve nerve 
regeneration and reduce perineural scar formation and adhesion after sciatic nerve repair 
[70]. It has been confirmed that direct application of HA‐carboxymethylcellulose in tran‐
sected nerves may limit axonal outgrowth by contact with regenerating axons; therefore, HA‐ 
carboxymethylcellulose barriers may prove to be a tool to prevent neuroma formation through 
inhibiting axonal growth [71]. On the contrary, according to some other studies, the role of HA 
solution in axonal outgrowth is dose‐dependent, because high dose of HA (100–1000 μg/ml) 
 topically used is characterised by significantly increased axonal outgrowth compared with 
HA solution (10 μg/ml) applied in the control group, in which axonal outgrowth did not 
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occur [72]. Some authors describe the early effect on nerve regeneration of continuous local 
delivery of nerve growth factor (NGF) and the local incorporation of HA inside a newly man‐
ufactured nerve conduit material from fresh human amniotic membrane [73]. Additionally, 
other authors have demonstrated that the combination of vascular endothelial growth factor 
(VEGF) gene therapy and a HA film sheath‐enriched microenvironment may synergistically 
promote peripheral nerve regeneration [74]. The microenvironment of neuron cells plays a 
crucial role in regulating neural development and regeneration [75].
HA and its derivatives may also promote regeneration of injured nerves through realignment 
of the fibrin matrix, and they can provide a suitable environment for axonal ingrowths [25]. In 
another animal experimental study, a single topical dose of HA enhanced the nerve regenera‐
tion process in hindlimb rat and rabbit models by preventing perineural scar formation after 
peripheral nerve repair [31, 76]. New data in the literature have shown that HA‐based bioma‐
terials have been applied in a wide range of medical and biological fields and play important 
roles in neural regeneration [75].
3. Tacrolimus
Tacrolimus, also known as FK506 or Fujimicin (C44H69O12), is a macrolide immunosuppres‐
sive drug that is approved for the prevention of allograft rejection [25], but it is well known 
that tacrolimus can also increase nerve regeneration and facilitate allografting of nerves via 
immunosuppression [18]. Chemically, tacrolimus is a 23‐membered macrolide lactone. It 
is a powerful and selective anti‐T‐lymphocyte agent that was discovered in 1984 and later 
approved by the U.S. Food and Drug Administration (FDA). This agent, isolated from the fun‐
gus Streptomyces tsukubaensis, has a mechanism of action similar to that of cyclosporin A. The 
first preliminary report on FK506 was presented in 1986 at the 11th International Congress of 
the Transplantation Society [77], and the first experimental reports were published in 1987 
[78–80]. These early reports demonstrated that FK506 is a potent immunosuppressant that 
acts in vitro via inhibiting interleukin 2 (IL‐2) production, as well as by inhibiting the response 
of mixed lymphocyte cultures at concentrations 32–100 times lower than that of cyclosporin 
A [81]. It means that despite similar mechanisms of action, tacrolimus is 50–100 times more 
potent than cyclosporin A [82].
Tacrolimus is able to modulate the immune system, inhibit T‐cell function by binding to FK 
binding proteins (FKBP) and mediate immunosuppression by inhibiting calcineurin and cal‐
cium and calmodulin‐dependent phosphatase. The primary biological effect of calcineurin 
inhibition includes the decrease of the production of inflammatory cytokines such as tumour 
necrosis factor (TNF)‐α, interleukin‐2 and interferon‐γ [28]. The drug’s immunosuppressive 
effects are mediated largely through FKBP12, which is involved in intracellular calcium flux 
and cycle regulation [83]. Tacrolimus realises its effect by binding to its receptors (FKBP12 and 
FKBP52). The FKBP12 receptors are responsible for immunosuppressive effects, whereas the 
FKBP52 receptors are related to neuroregenerative effects. These effects of tacrolimus have 
been shown experimentally in multiple models of nerve injury during the past decade when 
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tacrolimus was used in sub‐immunosuppressive doses, and these findings have stimulated 
interest in characterising its neurophysiologic effects on nerve regeneration [84]. Tacrolimus 
sustains nerve regeneration with both systemic and local administration [85]. In vitro and in 
vivo experimental models have proven that tacrolimus increases neurite elongation and accel‐
erates the rate of peripheral nerve regeneration [29]. In addition, there is evidence from in vivo 
experimental studies that highlight that tacrolimus has a neuroprotective role in the central 
nervous system through its direct impact on its various cell populations [86]. Recently, some 
studies have demonstrated the effect of tacrolimus in spinal surgery where it was found that 
topical application of tacrolimus could inhibit fibroblast proliferation and prevent epidural 
scar adhesion after laminectomy in a rat model [87], and it is worth mentioning that tacroli‐
mus has been successfully used topically in spinal cord trauma for neuroprotection and local 
regeneration [88].
Tacrolimus is an essential drug for the conventional immunosuppression regimen for solid 
organ transplantation. The use of tacrolimus in post‐transplant immunosuppressive regimens 
can enhance nerve regeneration and the growth of axon sprouts into donor tissue [89]. It has 
been demonstrated that tacrolimus has a powerful effect on promoting axon regeneration 
through its immunosuppressive and neurotrophic action [90]. This (neurotrophic) action can 
be completely prevented in vitro by the addition of a monoclonal antibody against FKBP52 [84].
The topical effects of tacrolimus on peripheral nerve have not been well investigated to date 
and the exact mechanism by which tacrolimus affects nerve regeneration is unclear, but out‐
comes data, so far, have been promising [89]. Additionally, the results of the use of tacrolimus 
in peripheral nerve regeneration differ in the literature. The relative variability of the results 
of experimental studies of nerve injures can be explain by the variety of models and testing 
methods used [91]. Prior studies have shown that FK506‐FKBP12 interaction may lead to a 
neuroregenerative effect through increased neuronal expression of a growth cone‐associated 
protein GAP‐43, but there is evidence that this occurs through inactivation of neuronal nitric 
synthetase [92, 93]. Moreover, axon regeneration from tacrolimus is realised predominantly 
through its binding to FKBP‐12, which activates GAP‐43 and the transforming growth fac‐
tor (TGFb1) pathway [26]. Tacrolimus can promote peripheral nerve regeneration through 
reducing scar formation; however, little is known about how tacrolimus reduces scar forma‐
tion [94, 95]. Que et al. suggest that tacrolimus‐induced fibroblast apoptosis contributes to 
the suppression of fibroblast proliferation and then causes the reduction of scar formation in 
the damaged nerve; in fibroblasts, apoptosis of tacrolimus involves c‐Jun N‐terminal kinase 
(JNK) and extracellular‐signal‐regulated kinase [94].
Some studies have shown a positive effect of tacrolimus after it was used in different allograft 
and isographs. Earlier axon regeneration in allografts with FK506 compared to allografts with‐
out FK506 was demonstrated experimentally [96]. Systemic application of tacrolimus at doses 
of 0.6 mg/kg found the amount of myelin debris in autologous nerve grafts to be decreas‐
ing [97]. This can be explained by the reduction of macrophage infiltration after tacrolimus 
administration. The reduction of scar formation at the site of nerve repair by the above‐men‐
tioned mechanisms has been associated with better morphologic and nerve function recovery. 
Recently, we published two original articles that compare the effects of HA and FK‐506 on 
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nerve regeneration. We found that our electrophysiological and biomechanical measurements 
as well as our results of functional evaluations indirectly indicate that the effects of HA and 
FK506 on nerve regeneration are similar [98, 99].
4. Cyclosporin A
Cyclosporin A is a neutral lipophilic cyclic undecapeptide that was isolated in 1971 from the 
fungus Tolypocladium inflatum and came into medical use in 1983 [100]. Its immunosuppressive 
function was first reported in 1972 by Sandoz Laboratories [101]. Discovery of cyclosporine A 
has revolutionised transplantation medicine, which requires the application of immunosup‐
pressive therapy. Cyclosporin has been widely applied as an immunosuppressive substance 
in organ transplantation in association with other drugs, both in vital and non‐vital organs, 
such as skin, nerve and muscles. It is known that cyclosporin A has similar immune‐suppress‐
ing characteristics to tacrolimus, but tacrolimus has a more potent effect with equal volumes 
of drug [95]. There are data in the literature that cyclosporin A was used experimentally in 
order to investigate its anti‐scarring effects on peripheral nerves both ultrastructurally and in 
gross post‐surgical and histopathological analyses [102]. Cyclosporin’s mechanism of action 
in nerve regeneration remains controversial [103]. However, probable mechanisms include 
inhibiting white blood cell proliferation and/or differentiation and inhibiting Ca2+‐dependent 
cell injury [104]. Besides the above‐mentioned mechanism, cyclosporin A acts with other 
anti‐inflammatory effects in preventing scar formation because it can block the transcription 
of cytokine genes in activated T cells, whereas on the another hand, it is well established 
that cyclosporin A inhibits the phosphatase activity of calcineurin through the formation of 
a complex with cyclophilin, which regulates nuclear translocation and subsequent activation 
of nuclear factor of activated T cells (NFAT) transcription factors [105]. Calcineurin plays an 
important role in the T‐cell receptor‐mediated signal transduction pathway and is identified 
as the common target for cyclosporin A and tacrolimus [106].
The role of cyclosporin A in peripheral nerve regeneration after peripheral nerve allograft‐
ing has been investigated in experimental models immunosuppressed with cyclosporine for 
more than two decades [107]. It is worth mentioning that most of these studies were concen‐
trated on allograft survival, rather than on the direct effect of cyclosporin A on peripheral 
nerve regeneration [103]. Some authors have investigated the efficacy of cyclosporine A in 
large‐ and small‐diameter nerve grafts as well as in long and short allografts. They have found 
better nerve regeneration in large‐diameter nerve grafts than in small‐diameter nerve grafts, 
whereas with regard to the length of the grafted nerve, short nerve allografts give higher axon 
counts than long ones, the same as with autografts [108]. Recently published data suggest that 
even though cyclosporin A is effective at reducing graft rejection, axon regeneration is still 
superior in autografts versus immunosuppressed allografts [109]. Furthermore, cyclosporin 
A effectively prevented postoperative epineurial fibrosis on rat sciatic nerves after peripheral 
nerve surgery with no adverse effects after topical application [102]. The application of cyclo‐
sporin A in a silicon conduit neurorrhaphy resulted in improvement of functional recovery 
and quantitative morphometric indices of sciatic nerves in diabetic rats [110].
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5. Melatonin
Melatonin, which is also known as N‐acetyl‐5‐methoxytryptamine, is a hormone and was first 
identified in bovine pineal extracts [35]. Melatonin is the main hormone of the pineal gland 
and is an important signalling molecule that occurs in many organisms as well as in plants and 
fungi [33]. The pineal gland is in the middle of the brain and secretes melatonin, a hormone 
that regulates when you sleep at night and wake up in the morning, as well as other numer‐
ous aspects of circadian biology [111]. Melatonin has an effect on the morphologic features 
of the nerve tissue, suggesting its neuroprotective, free‐radical scavenging and antioxidative 
and analgesic effects in degenerative diseases of peripheral nerves [25]. There are different 
opinions among authors regarding the protective effect of melatonin in stimulation of periph‐
eral regeneration, because some authors have reported toxic effects of melatonin on periph‐
eral nerves [33]. However, nowadays there is enough evidence from the literature showing 
that melatonin has a useful effect on axon length and sprouting after traumatic events to 
peripheral nerves [34]. The beneficial effects of melatonin administration on the recovery of 
injured nerves may be attributed to its antioxidant properties [112]. Melatonin has an effect on 
superoxide dismutase, which is an important antioxidative enzyme that is involved in redox 
regulation of regulative stress, and would exert melatonin’s beneficial effects by preserving 
the superoxide dismutase reactivity following peripheral nerve injury [113]. The rhythm of 
melatonin defines the activity of glutathione peroxidase and consequently also glutathione 
reductase. It is thought that the involvement of melatonin in the control of redox processes 
depends on its high‐affinity binding to cytosolic quinone reductase 2, previously believed to 
be a melatonin receptor [114]. Through a variety of experimental neuropathologies involving 
nitric oxide (NO), it was confirmed that melatonin exerts its neuroprotective role after periph‐
eral axotomy via reduction of oxidative damage [115]. The neuronal isoform of nitric oxide 
synthetase (nNOS), an NADPH‐dependent diaphorase, is considered to play a role in moto‐
neuron death induced by nerve transection. In addition, it is known that exogenous melatonin 
can prevent neuropathy development via the inhibition of lipid peroxidation in renal tissue 
and the inhibition of TGF‐β, which limits the effects against fibrosis [116]. Furthermore, data 
show that melatonin can significantly promote Schwann cell proliferation and can improve 
nerve regeneration after peripheral nerve injury via this mechanism both in vitro and in vivo. 
The functional recovery of damaged nerves was estimated by the amount of Schwann cells 
and the number of re‐innervated muscle motor end‐plate targets [117]. Furthermore, it is 
worth mentioning that Turgut et al. have experimentally demonstrated in rats that melatonin 
prevents neuroma formation after transacting the sciatic nerve by enhancing axonal regenera‐
tion [118]. Recently, some studies have shown the positive effect of melatonin on preventing 
scar formation, increasing nerve regeneration and improving functional recovery [119, 120]. 
However, the exact mechanisms by which melatonin limits fibrosis are currently unclear.
6. Methylprednisolone
Methylprednisolone is an anti‐inflammatory pharmacological agent that has found  widespread 
use in treatment of many pathological disorders in humans. It has also been experimentally 
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investigated intensely for preventing scar formation and nerve regeneration because it is 
considered to have a neuroprotective role. Generally, glucocorticoids are anti‐inflammatory 
substances that are often used to alleviate tissue oedema and trauma‐induced inflammatory 
response because they can down regulate the expression of pro‐inflammatory factors, such 
as tumour necrosis factor‐α and interleukin‐1β [121]. These pro‐inflammatory factors can 
increase the expression of induced nitric oxide synthase in the injured region, leading to nitric 
oxide production and cell apoptosis [122]. There are some mechanisms by which glucocor‐
ticoids can express their anti‐inflammatory effects in central and peripheral nerve system. 
However, one possible mechanism by which methylprednisolone inhibits nerve inflamma‐
tion is its inhibition of CD3‐positive inflammatory cell infiltration of local tissue [123]. It was 
found that higher doses of methylprednisolone have a neuroprotective role in injured nerves 
through inhibition of oxygen‐free radical‐induced lipid peroxidation [124]. Therefore, through 
inhibition of lipid peroxidation, methylprednisolone can retard both anterograde and retro‐
grade nerve degeneration after peripheral nerve injury. Moreover, the steroid expresses its 
anti‐inflammatory effects via inhibition on responsive cells and consequently recruitment of 
macrophages [125]. Regarding these anti‐inflammatory effects, inhibition of phospholipase 
A2 activity should be mentioned, along with prevention of granulocyte, mast cell and mac‐
rophage degranulation, inhibition of macrophage migration‐inhibitory factor and stabilisa‐
tion of the lysosomal membrane, which are beneficial for treating injured nerves [39]. In the 
same study, the effect of preoperative locally administered dexamethasone on the recovery of 
crushed nerves was examined, and the authors concluded that local dexamethasone is more 
effective than systemic dexamethasone [39]. Systemic application in rats of moderate doses of 
methylprednisolone, i.e. 15–30 mg/kg, can effectively increase peripheral nerve regeneration, 
and it was also found that local administration of the drug can have the same positive effects 
as those of systemic administration while reducing systemic side effects [126]. Moreover, it 
was found that dexamethasone loaded in silicone tubes can improve functional recovery and 
morphometric indices of the sciatic nerve, and it was confirmed that topical administration 
of dexamethasone on peripheral nerve offers the benefits of cost savings as well as avoiding 
the complications associated with systemic administration [38]. The effect of methylpredniso‐
lone in suppressing scar formation and improving axonal regeneration after transection and 
suture of rat peripheral nerves was described many years before in rats [36].
Recent experimental studies have demonstrated that topical application of methylpredniso‐
lone can be realised using various methods, for example, in various materials such as silicon 
tubes [38], amniotic membranes [125] and microsphere sustained‐release membranes [126], in 
order to avoid the rapid destruction of methylprednisolone at the site of nerve repair.
7. Vitamin B12
Vitamin B12, also called cobalamin, is a water‐soluble vitamin with multiple functions in 
organisms, although in comparison with other nutrients, the body needs them in relatively 
small amounts. It is naturally present in animal products, fish, meat, poultry, eggs, milk and 
milk products [127]. There are several forms of vitamin B12, which contains mineral cobalt, so 
for this reason, compounds with vitamin B12 activity are collectively called cobalamins and 
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the active forms are methylcobalamin and 5 deoxyadenosylcobalaminin [128]. Vitamin B12 as 
a coenzyme induces conversion of homocysteine to methionine in order to facilitate synthesis 
of nucleic acids and proteins. Therefore, it accomplishes the following essential nerve func‐
tion, such as promotion of nerve regeneration owing to axoplasm flow within the neuraxon, 
in order to normalise the neuraxon’s skeleton protein transportation as well as accelerate 
the formation of the myelin sheath [129]. Vitamin B12 in combination of B1 (thiamine) and 
B6 (pyridoxine) reduced degenerating processes in the nervous system, and therefore, this 
combination has been clinically administered [130]. Furthermore, this vitamin is involved 
in the metabolism of every cell in the human body, especially affecting DNA synthesis and 
fatty acid and amino acid metabolism [131]. It is known that B12 deficiency leads to defi‐
ciency in methionine, which is required for the synthesis of both phospholipids and myelin; 
therefore, it is an essential element in the maintenance of nerve functions because it induces 
synthesis of the myelin sheath and improves nerve conduction velocity. In addition, it was 
found that vitamin B12 increased the number of Schwann cells and myelinated nerve fibres, 
and the diameter of axons, through which effects it can promote the regeneration of myelin‐
ated nerve fibres and the proliferation of Schwann cells [132]. In addition, vitamin B12 has 
shown antioxidant properties because it is also a good scavenger of reactive oxygen species 
and is suggested to be a good neuroprotectant. Moreover, vitamin B complex or vitamin B12 
can increase the expression of brain‐derived neurotrophic factor (BDNF) in injured nerves at 
both mRNA and protein levels, therefore promoting the regeneration and functional recovery 
of injured nerves through increasing BDNF expression [41]. Some authors have shown that 
vitamin B12 provides a basis for more beneficial treatments of nervous disorders through 
both systemic and local delivery of high doses of methylcobalamin to target organs, which 
has been shown to have the potential to treat peripheral nerve injury [40]. Inasmuch as the 
amount of vitamin B complex and vitamin B12 vary in cases of crush nerve injuries, it is nec‐
essary to administrate these vitamins in the acute phase of nerve injury in order to enhance 
nerve regeneration [42].
8. Riluzole
Riluzole (2‐amino‐6‐trifluoromethoxy‐benzothiazol) is a benzothiazole anti‐convulsant and 
the only U.S. Food and Drug Administration (FDA)‐approved drug to treat amyotrophic lat‐
eral sclerosis (ALS) [133]. Riluzole is a sodium/glutamate antagonist that has been shown to 
have a neuroprotective effect, recently entered clinical testing for spinal cord injury [134] and 
currently is under Phase III clinical trial for the treatment of spinal cord injury (ClinicalTrials.
gov: NCT01597518) [135]. Its neuroprotective effects are a result of the blockade of sodium 
channels and, consequently, prevention of Ca2+ overflow [136]. In experimental trials in ani‐
mal models, it was successfully used to reduce symptoms in neurodegenerative disease and 
neural tissue injury, and these effects can be explained by its inhibition of presynaptic gluta‐
mate release through blocking voltage‐gated sodium channels [133]. It is known that in vitro 
application of riluzole to adult dorsal root ganglion neurons gives a neuroprotective effect 
via promotion of neurite outgrowth in terms of number, length and branch [137]. For nerve 
Peripheral Nerve Regeneration - From Surgery to New Therapeutic Approaches Including Biomaterials and Cell-Based
Therapies Development
156
regeneration after nerve injury, neurite outgrowth of surviving neurons is very important in 
order to reinervate target tissue. In addition, riluzole inhibits neuro‐excitotoxicity in animal 
models of neural injury, and soon after its administration, it can sufficiently reduce pain from 
nerve root compression and can prevent development of neuronal dysfunction in the nerve 
root and the spinal cord [138]. Recently, riluzole was clinically approved for the treatment of 
motor neuron disease, and experimental research is now underway for the assessment of its 
role on nerve regeneration processes after peripheral nerve injury [46].
9. 4‐Aminopyridine
4‐Aminopyridine (4‐AP) is a potassium channel blocker with the chemical  formula  C
5
H
4
N─NH2 that it used as a research tool in order to classify the subtypes of the potassium channel [139]. 
It has shown clinical efficacy in the treatment of neurological disorders such as multiple scle‐
rosis [140]. The mechanisms of action of 4‐AP can explain by its effect in allowing impulse 
conduction in demyelinated axons by blocking K+ channels that allow leakage of K+ from these 
axons and thereby enabling axons to restore the level of depolarisation required for propaga‐
tion of action potentials [141]. Recently, there are data from literature that 4‐ aminopyridine 
is a potent small molecule with neuroregenerative properties that enhances both the speed 
and extent of functional recovery after acute peripheral nerve injury, because it promotes 
 remyelination [142]. The same authors have found that 4‐aminopyridine treatment enables 
differentiation between incomplete and complete lesions more rapidly compared with  existing 
approaches [142].
10. Verapamil
Verapamil belongs to the class of medications called calcium channel blockers. Besides its 
effects in the cardiovascular system, recently some experimental studies have investigated 
the role of verapamil in the peripheral nervous system, and it has been shown to reduce scar 
formation through inhibiting fibroblast adhesion and proliferation in vitro [143]. However, it 
is not clear whether topical application of verapamil after surgical nerve repair in vivo could 
prevent scar formation and promote nerve regeneration [44]. Apparently, this role of vera‐
pamil consists of stimulation of the endogenous anti‐inflammatory reaction and decreasing 
pro‐inflammatory processes by a channel blocker, therefore causing pain modulation or nerve 
regeneration [43]. The effect of calcium channel blockers in the reduction of scar formation 
was first reported by Lee and Ping [144]. There are two mechanisms by which verapamil can 
prevent scar formation: by reducing the biological activity of cells through inhibiting signal 
transduction inside and outside fibroblasts, and by suppressing the synthesis and secretion of 
collagen and extracellular matrix through changing fibroblast morphology [44].
The overall effects and mechanisms of the above‐mentioned pharmacological agents in the 
prevention of scar formation and improved nerve regeneration are presented in Table 1.
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Pharmacological 
agents
Effects Mechanisms of action References
Hyaluronic acid Reduce the extent of scar 
formation and nerve 
adhesions
Via proliferation and chemotaxis 
of granulocyte phagocytosis and 
degranulation, and macrophage motility
Ozgenel [31] and 
Park et al. [70]
Stimulator of interleukin‐1 (IL‐1) 
production, which affects (decreases) 
fibroblast proliferation and collagenase 
production
Hiro et al. [30]
Tacrolimus (FK506) Neuroprotective role 
via reduction of scar 
formation
Through encouraging fibroblast 
apoptosis, it contributes to the 
suppression of fibroblast proliferation. 
Fibroblast apoptosis by tacrolimus 
involves c‐Jun N‐terminal kinase (JNK) 
and extracellular‐signal‐regulated 
kinase
Que et al. [94]
Neuroregenerative role FK506‐FKBP12 interaction may lead 
to a neuroregenerative effect through 
increased neuronal expression of growth 
cone‐associated protein GAP‐43 that 
probably occurs through inactivation of 
neuronal nitric synthetase
Dawson et al. [92] 
and Madsen et al. 
[93]
By increased neurite elongation 
and accelerating the rate of nerve 
regeneration
Konofoas and Terzis 
[29]
Cyclosporin A Anti‐scarring effects and 
nerve regeneration on 
peripheral nerves
Probable mechanisms include inhibiting 
white blood cell proliferation and/
or differentiation and inhibiting Ca2+‐
dependent cell injury
Erkutlu et al. [104]
It is well established that cyclosporin 
A inhibits the phosphatase activity 
of calcineurin through the formation 
of a complex with cyclophilin, which 
regulates nuclear translocation and 
subsequent activation of nuclear factor 
of activated T cells (NFAT) transcription 
factors
Matsuda and Koyasu 
[105]
Melatonin Induces axon length and 
sprouting after traumatic 
events to peripheral nerves
Via its effect on superoxide dismutase, 
which is an important antioxidative 
enzyme that is involved in redox 
regulation of regulative stress
Chang et al. [113]
Improves nerve 
regeneration
Via reduction of oxidative damage, 
melatonin exerts its neuroprotective role 
after peripheral axotomy in a variety 
of experimental neuropathologies that 
involve nitric oxide (NO)
Chang et al. [115]
Limits fibrosis and 
neuroma formation
Through promoting Schwann cell 
proliferation
Chang et al. [117]
Exact mechanisms through which 
melatonin imparts these effects are 
currently unclear
Turgut et al. [118]
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11. Discussion
There have been many efforts to diminish scar formation and perineural adhesion as well as 
to improve nerve regeneration after microsurgical nerve repair. Various surgical techniques 
and several different pharmacological agents have been used for this purpose. The evalua‐
Pharmacological 
agents
Effects Mechanisms of action References
Methylprednisolone Neuroprotective role By its inhibition of CD3‐positive 
inflammatory cell infiltration in local 
tissue and consequently recruitment of 
macrophages
Feng and Yuan [123]
Anti‐inflammatory effects Through inhibition of oxygen‐free 
radical‐induced lipid peroxidation
Hall [124]
Vitamin B12 Nerve regeneration Owing to axoplasm flow within 
the neuraxon, in order to normalise 
the neuraxon’s skeleton protein 
transportation as well as accelerating the 
formation of the myelin sheath
Wang et al. [129]
Neuroprotectant Through increasing the number of 
Schwann cells and myelinated nerve 
fibres, and the diameter of axons
Lopatina et al. [132]
Through antioxidant properties, because 
it is also a good scavenger of reactive 
oxygen species
Sun et al. [41]
Riluzole Neuroprotectant Through blockade of sodium channels, 
and consequently prevention of Ca2+ 
overflow
Fehlings et al. [136]
Inhibits 
neuro‐excitotoxicity
Through reducing pain from nerve root 
compression, it can prevent development 
of neuronal dysfunction in the nerve root
Nicholson et al. [138]
4‐Aminopyridine 
(4‐AP)
Neuroregenerative 
properties
Through its effect in allowing impulse 
conduction in demyelinated axons by 
blocking K+ channels that allow leakage 
of K+ from these axons and thereby 
enabling axons to restore the level of 
depolarisation required for propagation 
of action potentials
Hayes [141]
Verapamil Reduce scar formation 
and promote nerve 
regeneration
There are two mechanisms by which 
verapamil can prevent scar formation: by 
reducing the biological activity of cells 
through inhibiting signal transduction 
inside and outside fibroblasts, and by 
suppressing the synthesis and secretion 
of collagen and extracellular matrix 
through changing fibroblast morphology
Han et al. [44]
Table 1. The effects and mechanisms of pharmacological agents in nerve regeneration.
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tion of the effects of these pharmacological agents in the prevention of scar formation and 
nerve regeneration in experimental animals is performed by electrophysiological measure‐
ments and through assessing functional recovery, whereas after sacrificing the animals, other 
methods have been used, such as macroscopic, histomorphometric, immunohistochemical 
and biomechanical techniques [70, 91, 98, 99]. Ozgenel found that nerves treated with HA 
have a significant reduction in perineural thickness compared to nerves treated with just 
saline (P < 0.05). Besides that, this author found better mean conduction velocities (MCVs) 
and faster functional recovery in HA‐treated nerves (0.82 ± 0.08 m/s) compared with nerves 
treated with saline, in which the MCV was 0.76 ± 0.04 m/s (P < 0.05) [31]. Park et al. found 
that topical application of HA carboxymethylcellulose solutions in rats significantly reduced 
nerve adherence score and the number of cellular components compared with the saline 
group (control group) (P < 0.05) [70]. The authors concluded that HA carboxymethylcellulose 
solutions improved nerve regeneration and reduced perineural scar formation and adhesion 
after sciatic nerve repair [70]. Furthermore, the same results were demonstrated by Adanali 
et al. in rabbit sciatic nerves where they used HA carboxymethylcellulose membranes in the 
experimental group and saline in the control group; they observed that adhesion in the sur‐
rounding tissues was significantly less in the HA carboxymethylcellulose membranes group 
than in the saline group [69]. Ikeda et al. found that local application of HA in the sciatic nerve 
was the most effective at reducing extraneural and intraneural connective tissue, compared 
with the steroid and saline groups [145]. By electrophysiological measurements, Ikeda et al. 
also found that the latencies of the HA and steroid groups were much shorter than that of the 
neurolysis group (2.14 ± 0.20, 1.92 ± 0.11 and 1.91 ± 0.15 m/s, respectively), but longer than 
that of the control group (1.68 ± 0.07 m/s). Similar results were found by histological examina‐
tion, because scar tissue in the neurolysis group was thicker and more voluminous than that 
in the HA group or the steroid group [145]. In addition, Zor et al. found significantly less scar 
formation (P < 0.01) and significantly higher peak amplitudes in rats (P < 0.01) that received 
a combination treatment of vascular endothelial growth factor gene therapy with HA [74].
Shahraki et al. demonstrated earlier axon regeneration in allografts with FK506 compared to 
allografts without FK506 (P < 0.05) [96]. Yan et al. found that short treatment courses of 10 and 
20 days with FK506 (in the graft model) were sufficient to reduce functional recovery time by 
15 and 21%, respectively, compared with negative controls assessed by walking track analy‐
sis [90]. In addition, via a functional study, Azizi et al. confirmed faster recovery of the regen‐
erated axons in the inside‐out vein graft/FK506 group than that for the inside‐out vein graft 
without FK506 (control group) (P < 0.05). The same statistically significantly difference was 
found when comparing these groups regarding the mean gastrocnemius muscle weight ratio 
(P < 0.05) [91]. Que et al. showed that scar area had a significant positive correlation with the 
fibroblast number, as detected by linear correlation analysis [94]. Other authors reported that 
tacrolimus can increase the number of axons and their myelinated axons by 40% and reduce by 
half the time to neurological recovery [29]. Furthermore, Li et al. found that after application 
of FK506 loaded in a chitosan guide, the amplitude and velocity of compound muscle action 
potential (CMAP) reached 60 and 73% of the control values, respectively [146].
In order to compare the effects of HA and FK506 on peripheral nerve regeneration in rabbits 
after the drugs were topically applied at the site of sciatic nerve, we used electrophysiologi‐
cal, macroscopic and microscopic methods, while functional assessment was performed via 
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toe‐spreading reflex. According to our results, HA and FK506 appear to have similar effects 
(P > 0.05) with respect to preventing scar formation and improving nerve regeneration com‐
pared with saline (P < 0.05) [80, 98]. However, it should be mentioned that we observed no 
significant differences in biomechanical properties in the HA and FK506 groups compared to 
the saline group (P > 0.05) [99].
Çetinalp et al. demonstrated that animals treated with cyclosporin A had statistically sig‐
nificant lower perineural adhesion and better separability than the saline group (control 
group) (P < 0.0001) [102]. However, these authors did not find a significant difference in the 
wound‐healing characteristics or neurological functions between the treatment (cyclosporin 
A) group and the control group (P > 0.05) [102]. In an experimental rat sciatic nerve injec‐
tion injury model established by penicillin G potassium injection, Erkutlu et al. randomly 
divided rats into three groups based on the length of time after nerve injury induced by cyclo‐
sporin A administration (30 minutes, 8 or 24 hours), recorded electrophysiological measure‐
ments (compound muscle action potentials, pre‐injury, early post‐injury [within 1 hour]and 4 
weeks after injury) and then compared the results of the experimental groups with the control 
group. Finally, they found significant improvement of the compound muscle action potential 
amplitude value only when cyclosporin A was administered within 30 minutes of the injec‐
tion injury (P < 0.05) [104].
Turgut et al. examined the gross morphology of neuroma formation in the proximal nerve seg‐
ment via macroscopic and microscopic findings, and the surgical pinealectomy group with‐
out application of melatonin caused a proliferation of connective tissue and large neuroma 
formation at the proximal ends of transacted nerves compared with the surgical pinealectomy 
group and the group given melatonin (P < 0.005) [118]. In addition, Kaya et al. demonstrated 
a beneficial effect on axonal regeneration and functional recovery in the experimental group 
in which melatonin was applied after stripping of the epineurial vessels compared with other 
groups without melatonin application [119].
Recently, Sadraie et al. found that at 8 weeks after surgery, sciatic functional index, with‐
drawal reflex latency test, electrophysiological values and histological results in the amniotic 
membrane with the betamethasone group were improved compared to those in the control 
and sham groups (P < 0.05) [125]. Furthermore, Feng and Yuan found better and faster func‐
tional recovery in the dexamethasone‐administered group compared to other groups without 
dexamethasone (P < 0.05); therefore, they concluded that dexamethasone can promote func‐
tional recovery after sciatic nerve crush injury [123]. In addition, Sun et al. via morphological 
(by electron microscopy) and functional analysis observed that treatment with dexametha‐
sone or vitamin B12 alone, or treatment with both agents, led to a much larger number of 
Schwann cells and myelinated nerve fibres compared with that in the saline group (P < 0.05) 
[41]. Okada et al. showed in a rat sciatic nerve injury model that continuous administration of 
high doses of methylcobalamin can improve nerve regeneration and functional recovery [40].
According to Shortland et al., a single dose of 0.1 μM riluzole was sufficient to promote neu‐
ronal survival in neonatal dorsal root ganglion cultures, whereas repeated riluzole adminis‐
tration was necessary in adult cultures. For both types of injuries, riluzole enhanced neurite 
outgrowth (number, length and branch pattern) significantly more on the injured side in com‐
parison with the contralateral side [137].
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Tseng et al. found that once‐daily administration of 10 μg of 4‐aminopyridine enhanced the 
speed of recovery from crush injury when it was used as early as 3 days post‐injury in mice 
treated daily (beginning 24 hours post‐injury), and a significant improvement (>25%) in gait 
function was confirmed over the control groups (vehicle‐treated animals). Furthermore, at 
5 and 8 days post‐injury, 4‐AP‐treated mice showed statistically significant twofold greater 
levels of improvement than the control groups [142].
Han et al. carried out a study in which the right sciatic nerve of adult rats was transected 
and sutured, and then a gelfoam soaked with verapamil solution for 4 weeks was topically 
applied by them. The results showed that verapamil can inhibit the secretion of extracellu‐
lar matrix from fibroblasts in vivo through suppression of type I and III collagen secretion. 
Verapamil also increased the total number of axons as well as the number of myelinated axons 
more than in the control group, in which gelfoam soaked with physiological saline was topi‐
cally applied (P < 0.05) [44].
12. Conclusions
Generally, it should be mentioned that the most of the experimental research discussed in this 
chapter was conducted in rats and rabbits, in which the above‐mentioned pharmacological 
agents have been applied (mainly locally in sciatic nerve). The success of the regenerative 
process of nerve repair in experimental research can be evaluated using a variety of meth‐
ods, such as morphological, immunohistochemical, electrophysiological, biomechanical and 
functional evaluation. Some of the pharmacological agents described in this chapter are still 
only used for experimental purposes, whereas some of them are in clinical use for the treat‐
ment of various diseases, and now their neuroregenerative effects will also be explored in 
experimental animals. However, the success of nerve regeneration depends on the type and 
degree of nerve injury, age, repair time, operative techniques and the type of materials used. 
By combining appropriate dosages of these pharmacological agents with improved microsur‐
gical techniques for nerve repair, better experimental results may be achieved in the future, 
encouraging clinical application of these agents. However, it is understandable that complete 
regeneration and functional recovery will almost never be achieved, regardless of the opera‐
tive technique used or the type of pharmacological agent applied.
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